|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-2-4
|
|
pubmed:abstractText |
Docetaxel is the standard of care for patients with metastatic, castrate-resistant prostate cancer (CRPC). Gemcitabine is a nucleoside analogue with broad antitumor activity. In a phase 2 study of combined docetaxel and gemcitabine, the authors assessed its safety and activity in patients with chemotherapy-naive, metastatic CRPC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
117
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
752-7
|
|
pubmed:meshHeading |
pubmed-meshheading:20922803-Aged,
pubmed-meshheading:20922803-Aged, 80 and over,
pubmed-meshheading:20922803-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20922803-Castration,
pubmed-meshheading:20922803-Deoxycytidine,
pubmed-meshheading:20922803-Humans,
pubmed-meshheading:20922803-Male,
pubmed-meshheading:20922803-Middle Aged,
pubmed-meshheading:20922803-Neoplasm Metastasis,
pubmed-meshheading:20922803-Prostate-Specific Antigen,
pubmed-meshheading:20922803-Prostatic Neoplasms,
pubmed-meshheading:20922803-Taxoids
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
|
|
pubmed:affiliation |
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA. garciaj4@cff.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
